Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is funded by PER®.

Minimal Residual Disease and Its Impact on the Clinical Management of Patients With Leukemia

Release Date: April 06, 2020
Expiration Date: April 06, 2021
Media: Internet - based

Activity Overview

This continuing medical education (CME) activity is evaluation and assessment of minimal residual disease in the management of acute lymphoblastic leukemia.

Acknowledgement of Commercial Support

This activity is funded by PER®.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Complete the activity in its entirety.
  • Complete the post-activity assessment.
  • Complete the evaluation and request credit.
  • Learners may immediately download a CME certificate upon successful completion of these steps.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline the importance of minimal residual disease (MRD) assessment for the clinical management of patients with leukemia
  • Consider the different techniques used to detect MRD
  • Implement optimal strategies to use MRD assessment in clinic to optimize the outcomes of patients with leukemia


Elias Jabbour
Elias Jabbour, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

This activity was written by Physicians’ Education Resource, LLC® (PER®), editorial staff under faculty guidance and review.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Disclosures (Dr Jabbour): Grant Research Support: AbbVie, Adaptive Biotechnologies, Amgen Inc, Bristol-Myers Squibb, Novartis, Pfizer, Spectrum, Takeda.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By